

National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

made under section 85B of the

National Health Act 1953

**Compilation No. 93**

**Compilation date:** 1 February 2021

**Includes amendments up to:** PB 8 of 2021

**Registered:** 11 February 2021

**About this compilation**

**This compilation**

This is a compilation of the *National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)* that shows the text of the law as amended and in force on 1 February 2021 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

**Uncommenced amendments**

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Editorial changes**

For more information about any editorial changes made in this compilation, see the endnotes.

**Modifications**

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

**Self‑repealing provisions**

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

1 Name of Determination 1

4 Definitions 1

5 Determined price 1

6 Claimed price 1

7 Commonwealth payment of special patient contribution 2

Schedule 1—Determined and Claimed Prices 3

Schedule 2—Pharmaceutical benefits for which the Commonwealth will pay the special patient contribution 34

Endnotes 36

Endnote 1—About the endnotes 36

Endnote 2—Abbreviation key 37

Endnote 3—Legislation history 38

Endnote 4—Amendment history 43

1 Name of Determination

(1) This Determination is the *National Health (Price and Special Patient Contribution) Determination 2010*.

(2) This Determination may also be cited as PB 109 of 2010.

4 Definitions

(1) In this Determination:

***Act*** means the *National Health Act 1953*.

***approved ex‑manufacturer price*** has the same meaning as in subsection 84(1) of the Act.

***base‑priced drug*** in relation to a brand of a pharmaceutical item mentioned in Schedule 2 (the ***relevant brand***), means all brands of pharmaceutical items that have:

(a) the same drug as the relevant brand; or

(b) a drug in the same therapeutic group as that drug; and

for which no price is determined under section 85B of the Act.

***pack quantity*** has the same meaning as in subsection 84(1) of the Act.

Note: The Minister may determine one or more *pack quantities* for a brand of a pharmaceutical item under subsection 84AK(2) of the Act. The quantities determined are the quantities in manufacturer’s PBS packs.

***pricing quantity*** has the same meaning as in subsection 84(1) of the Act.

Note: Subsection 84AK(1) of the Act provides that the *pricing quantity* of a brand of a pharmaceutical item is the lowest *pack quantity* of any brand of the pharmaceutical item.

***special patient contribution*** has the meaning given by subsection 85B(5) of the Act.

5 Determined price

For subsection 85B(2) of the Act, the amount that is, for the purposes of Part VII of the Act, taken to be the appropriate maximum price for the pricing quantity of a brand of a pharmaceutical item mentioned in Schedule 1, is the price for the brand mentioned in the column headed ‘Determined Price’ for the pricing quantity mentioned in the column headed ‘Pricing Quantity/Pack Quantity’.

6 Claimed price

For subsection 85B(3) of the Act, the amount that is, for the purposes of Part VII of the Act, taken to be the price claimed by the responsible person for a pack quantity of a brand of a pharmaceutical item mentioned in Schedule 1, is the price for the brand mentioned in the column headed ‘Claimed Price’ for the pack quantity mentioned in the column headed ‘Pricing Quantity/Pack Quantity’.

7 Commonwealth payment of special patient contribution

(1) For subsection 85B(4) of the Act, the circumstances in which the Commonwealth is to pay the special patient contribution for a brand of a pharmaceutical item are:

(a) the brand of pharmaceutical item is mentioned in Schedule 2; and

(b) the brand has been prescribed in a circumstance mentioned for the brand in Schedule 2; and

(c) the prescription has been authorised by the Chief Executive Medicare in accordance with subsection (2) or (3).

(2) If the circumstance in which the brand is prescribed is a circumstance determined under paragraph 85(7)(b) of the Act, the prescription is taken to be authorised if:

(a) the circumstance requires compliance with authority required procedures for prescribing the brand; and

(b) the authority required procedures have been complied with.

(3) In any other case, a prescription is taken to be authorised if the prescription has been submitted and authorised in the way provided for in authority required procedures mentioned in an instrument made under section 85 of the Act.

(4) For this section, the pharmaceutical item is the listed drug mentioned in Schedule 2:

(a) in the form mentioned in Schedule 2 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 2 for the form of the listed drug.

Schedule 1—Determined and Claimed Prices

| Listed Drug | Form | Manner of Administration | Brand | Pricing Quantity/Pack Quantity | Determined  Price $ | Claimed  Price $ |
| --- | --- | --- | --- | --- | --- | --- |
| Acarbose | Tablet 100 mg | Oral | Glucobay 100 | 90 | 21.96 | 24.10 |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Fosamax Plus | 4 | 6.37 | 10.09 |
|  | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Fosamax Plus 70 mg/140 mcg | 4 | 6.37 | 10.09 |
| Allopurinol | Tablet 100 mg | Oral | Zyloprim | 100 | 2.26 | ‑ |
|  |  |  |  | 200 | ‑ | 7.75 |
|  | Tablet 300 mg | Oral | Zyloprim | 60 | 3.27 | 6.51 |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | Endep 10 | 50 | 2.33 | 4.15 |
|  | Tablet containing amitriptyline hydrochloride 25 mg | Oral | Endep 25 | 50 | 2.51 | 4.33 |
|  | Tablet containing amitriptyline hydrochloride 50 mg | Oral | Endep 50 | 50 | 2.88 | 4.70 |
| Amlodipine | Tablet 5 mg (as besilate) | Oral | Norvasc | 30 | 0.83 | 11.24 |
|  | Tablet 10 mg (as besilate) | Oral | Norvasc | 30 | 1.47 | 11.89 |
| Amlodipine with atorvastatin | Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | Oral | Caduet 5/40 | 30 | 3.78 | 8.43 |
|  | Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | Oral | Caduet 5/80 | 30 | 5.05 | 9.70 |
|  | Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | Oral | Caduet 10/10 | 30 | 2.89 | 7.54 |
|  | Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | Oral | Caduet 10/20 | 30 | 3.57 | 8.22 |
|  | Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | Oral | Caduet 10/40 | 30 | 4.42 | 9.07 |
|  | Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | Oral | Caduet 10/80 | 30 | 5.69 | 10.34 |
| Amlodipine with valsartan | Tablet 5 mg (as besilate)‑ 80 mg | Oral | Exforge 5/80 | 28 | 7.42 | 10.21 |
|  | Tablet 5 mg (as besilate)‑ 160 mg | Oral | Exforge 5/160 | 28 | 9.31 | 12.10 |
|  | Tablet 5 mg (as besilate)‑ 320 mg | Oral | Exforge 5/320 | 28 | 11.72 | 14.51 |
|  | Tablet 10 mg (as besilate)‑ 160 mg | Oral | Exforge 10/160 | 28 | 9.91 | 12.70 |
|  | Tablet 10 mg (as besilate)‑ 320 mg | Oral | Exforge 10/320 | 28 | 12.32 | 15.11 |
| Amlodipine with valsartan and hydrochlorothiazide | Tablet 5 mg (as besilate)‑ 160 mg‑ 12.5 mg | Oral | Exforge HCT 5/160/12.5 | 28 | 10.72 | 13.51 |
|  | Tablet 5 mg (as besilate)‑ 160 mg‑ 25 mg | Oral | Exforge HCT 5/160/25 | 28 | 12.13 | 14.92 |
|  | Tablet 10 mg (as besilate)‑ 160 mg‑ 12.5 mg | Oral | Exforge HCT 10/160/12.5 | 28 | 11.32 | 14.11 |
|  | Tablet 10 mg (as besilate)‑ 160 mg‑ 25 mg | Oral | Exforge HCT 10/160/25 | 28 | 12.73 | 15.52 |
|  | Tablet 10 mg (as besilate)‑ 320 mg‑ 25 mg | Oral | Exforge HCT 10/320/25 | 28 | 15.14 | 17.93 |
| Amoxicillin | Capsule 250 mg (as trihydrate) | Oral | Amoxil | 20 | 1.37 | 4.61 |
|  | Capsule 500 mg (as trihydrate) | Oral | Amoxil | 20 | 1.63 | 5.12 |
|  | Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil | 1 | 1.28 | 4.50 |
|  | Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil Forte | 1 | 1.59 | 4.90 |
|  | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 1 | 5.88 | 6.37 |
|  | Tablet 1 g (as trihydrate) | Oral | Maxamox | 14 | 1.47 | 2.47 |
| Amoxicillin with Clavulanic Acid | Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL | Oral | Augmentin Duo 400 | 1 | 1.90 | 6.40 |
|  | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo | 10 | 2.30 | 6.83 |
|  | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo forte | 10 | 2.58 | 8.38 |
| Atenolol | Tablet 50 mg | Oral | Tenormin | 30 | 1.06 | 13.58 |
| Betamethasone | Cream 200 micrograms (as valerate) per g, 100 g | Application | Betnovate 1/5 | 1 | 7.20 | 9.98 |
|  |  |  | Celestone‑M | 1 | 7.20 | 9.52 |
|  | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | 1 | 5.43 | 7.71 |
|  | Cream 500 micrograms (as valerate) per g, 15 g | Application | Betnovate 1/2 | 1 | 1.61 | 3.99 |
|  | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | 1 | 5.43 | 7.71 |
| Betaxolol | Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Betoptic | 1 | 6.75 | 11.18 |
| Bisacodyl | Suppositories 10 mg, 10 | Rectal | Dulcolax | 1 | 3.92 | 4.32 |
| Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | Oral | Bicor | 28 | 6.28 | 12.51 |
|  | Tablet containing bisoprolol fumarate 5 mg | Oral | Bicor | 28 | 7.84 | 14.07 |
|  | Tablet containing bisoprolol fumarate 10 mg | Oral | Bicor | 28 | 9.80 | 16.03 |
| Brimonidine | Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | Application to the eye | Alphagan | 1 | 11.10 | 12.42 |
| Brinzolamide | Eye drops 10 mg per mL, 5 mL | Application to the eye | Azopt | 1 | 13.23 | 17.67 |
| Calcitriol | Capsule 0.25 microgram | Oral | Rocaltrol | 100 | 14.99 | 17.12 |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | Atacand | 30 | 0.43 | 12.96 |
|  | Tablet containing candesartan cilexetil 8 mg | Oral | Atacand | 30 | 1.29 | 13.82 |
|  | Tablet containing candesartan cilexetil 16 mg | Oral | Atacand | 30 | 3.84 | 16.37 |
|  | Tablet containing candesartan cilexetil 32 mg | Oral | Atacand | 30 | 4.64 | 17.17 |
| Candesartan with Hydrochlorothiazide | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | Oral | Atacand Plus 16/12.5 | 30 | 4.12 | 16.65 |
|  | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | Atacand Plus 32/12.5 | 30 | 4.82 | 17.35 |
|  | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | Atacand Plus 32/25 | 30 | 5.59 | 18.12 |
| Captopril | Tablet 25 mg | Oral | Capoten | 90 | 4.51 | 8.85 |
|  |  |  | Zedace | 90 | 4.51 | 8.18 |
|  | Tablet 50 mg | Oral | Capoten | 90 | 8.89 | 12.52 |
|  |  |  | Zedace | 90 | 8.89 | 12.56 |
| Carbamazepine | Tablet 100 mg | Oral | Tegretol 100 | 100 | 5.47 | 6.86 |
|  | Tablet 200 mg | Oral | Tegretol 200 | 100 | 9.13 | 10.51 |
| Carbomer | Eye gel 2 mg per g, 10 g | Application to the eye | Viscotears | 1 | 2.62 | 6.20 |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Cellufresh | 1 | 5.45 | 7.38 |
|  | Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Celluvisc | 1 | 5.45 | 7.38 |
| Cefaclor | Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral | Ceclor | 1 | 3.11 | 10.55 |
|  | Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL | Oral | Ceclor | 1 | 3.31 | 10.75 |
|  | Tablet (sustained release) 375 mg (as monohydrate) | Oral | Ceclor CD | 10 | 3.50 | 10.94 |
| Cefalexin | Capsule 250 mg (as monohydrate) | Oral | Keflex | 20 | 1.59 | 5.09 |
|  | Capsule 500 mg (as monohydrate) | Oral | Keflex | 20 | 1.73 | 6.82 |
|  | Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 1.82 | 5.68 |
|  | Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL | Oral | Keflex | 1 | 2.10 | 7.39 |
| Ciprofloxacin | Eye drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Ciloxan | 1 | 8.92 | 10.95 |
| Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Cipramil | 28 | 1.21 | 11.15 |
| Clarithromycin | Tablet 250 mg | Oral | Klacid | 14 | 2.75 | 6.00 |
| Clomipramine | Tablet containing clomipramine hydrochloride 25 mg | Oral | Anafranil 25 | 50 | 5.52 | 9.63 |
| Clonazepam | Tablet 500 mcg | Oral | Rivotril | 50 | 2.65 | 3.51 |
| Codeine with Paracetamol | Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg | Oral | Panadeine Forte | 20 | 1.26 | 3.21 |
| Colchicine | Tablet 500 micrograms | Oral | Colgout | 30 | 3.70 | 6.40 |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | Androcur | 20 | 13.32 | 15.55 |
|  |  |  |  | 50 | ‑ | 34.36 |
|  | Tablet containing cyproterone acetate 100 mg | Oral | Androcur‑100 | 50 | 51.88 | 53.19 |
| Dexamethasone with Framycetin and Gramicidin | Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL | Application to the ear | Sofradex | 1 | 2.85 | 5.09 |
| Diazepam | Tablet 2 mg | Oral | Antenex 2 | 50 | 1.23 | 4.01 |
|  | Tablet 5 mg | Oral | Valium | 50 | 1.29 | 4.36 |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | Voltaren 25 | 50 | 1.37 | 2.97 |
|  | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Voltaren 50 | 50 | 1.91 | 5.12 |
| Dicloxacillin | Capsule 250 mg (as sodium) | Oral | Distaph 250 | 24 | 4.30 | 6.11 |
|  | Capsule 500 mg (as sodium) | Oral | Distaph 500 | 24 | 7.53 | 9.35 |
| Digoxin | Tablet 62.5 micrograms | Oral | Lanoxin‑PG | 200 | 3.24 | 5.62 |
|  | Tablet 250 micrograms | Oral | Lanoxin | 100 | 3.47 | 5.85 |
| Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | Cardizem CD | 30 | 6.25 | 8.02 |
|  | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | Cardizem CD | 30 | 8.45 | 10.22 |
|  | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | Cardizem CD | 30 | 11.08 | 12.84 |
|  | Tablet containing diltiazem hydrochloride 60 mg | Oral | Cardizem | 90 | 5.64 | 7.40 |
| Diphenoxylate with Atropine | Tablet containing diphenoxylate hydrochloride 2.5 mg with atropine sulfate monohydrate 25 micrograms | Oral | Lomotil | 20 | 1.66 | 3.06 |
| Donepezil | Tablet containing donepezil hydrochloride 5 mg | Oral | Aricept | 28 | 9.36 | 12.78 |
|  | Tablet containing donepezil hydrochloride 10 mg | Oral | Aricept | 28 | 9.36 | 17.73 |
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosopt | 1 | 9.85 | 10.78 |
| Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Oral | Dothep 25 | 50 | 2.39 | 4.20 |
|  | Tablet containing dosulepin hydrochloride 75 mg | Oral | Dothep 75 | 30 | 2.39 | 4.20 |
| Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | 7 | 1.36 | 4.11 |
|  |  |  | Mayne Pharma Doxycycline | 7 | 1.36 | 2.79 |
|  |  |  | Doryx | 21 | ‑ | 12.45 |
|  |  |  | Mayne Pharma Doxycycline | 21 | ‑ | 7.07 |
|  | Capsule 50 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | 25 | 2.17 | 6.83 |
|  |  |  | Mayne Pharma Doxycycline | 25 | 2.17 | 4.58 |
| Duloxetine | Capsule 30 mg (as hydrochloride) | Oral | Cymbalta | 28 | 3.86 | 11.30 |
|  | Capsule 60 mg (as hydrochloride) | Oral | Cymbalta | 28 | 5.51 | 12.95 |
| Dutasteride | Capsule 500 micrograms | Oral | Avodart | 30 | 15.50 | 22.01 |
| Dutasteride with tamsulosin | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms | Oral | Duodart 500ug/400ug | 30 | 18.29 | 21.55 |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | Renitec | 30 | 2.87 | 8.83 |
|  | Tablet containing enalapril maleate 20 mg | Oral | Renitec 20 | 30 | 3.65 | 9.60 |
| Enalapril with Hydrochlorothiazide | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | Oral | Renitec Plus 20/6 | 30 | 4.99 | 11.50 |
| Eprosartan | Tablet 400 mg (as mesilate) | Oral | Teveten | 28 | 5.75 | 9.00 |
|  | Tablet 600 mg (as mesilate) | Oral | Teveten | 28 | 14.41 | 17.66 |
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | Lexapro | 28 | 1.95 | 12.85 |
|  | Tablet 20 mg (as oxalate) | Oral | Lexapro | 28 | 1.97 | 13.19 |
| Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexium | 30 | 5.87 | 9.20 |
|  | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexium | 30 | 9.97 | 13.30 |
| Esomeprazole and clarithromycin and amoxicillin | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) | Oral | Nexium Hp7 | 1 | 23.65 | 26.98 |
| Exemestane | Tablet 25 mg | Oral | Aromasin | 30 | 51.62 | 55.34 |
| Ezetimibe | Tablet 10 mg | Oral | Ezetrol | 30 | 12.71 | 15.50 |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | Oral | Rosuzet Composite Pack | 1 | 14.27 | 17.06 |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | Oral | Rosuzet Composite Pack | 1 | 15.02 | 17.81 |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | Oral | Rosuzet Composite Pack | 1 | 15.96 | 18.75 |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | Oral | Rosuzet Composite Pack | 1 | 17.35 | 20.14 |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 30 | 2.61 | 4.55 |
|  | Tablet 5 mg (extended release) | Oral | Plendil ER | 30 | 3.75 | 5.69 |
|  | Tablet 10 mg (extended release) | Oral | Plendil ER | 30 | 6.79 | 8.73 |
| Fluconazole | Capsule 50 mg | Oral | Diflucan | 28 | 9.90 | 15.48 |
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Prozac 20 | 28 | 3.45 | 4.55 |
|  | Tablet, dispersible, 20 mg (as hydrochloride) | Oral | Prozac Tab | 28 | 3.45 | 4.55 |
| Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by Mouth | Flixotide | 1 | 15.65 | 18.44 |
|  | Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by Mouth | Flixotide | 1 | 28.80 | 31.59 |
| Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 125/25 | 1 | 34.56 | 38.28 |
|  | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 250/25 | 1 | 46.78 | 50.50 |
| Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | Luvox | 30 | 5.26 | 8.52 |
|  | Tablet containing fluvoxamine maleate 100 mg | Oral | Luvox | 30 | 7.97 | 11.23 |
| Furosemide | Tablet 20 mg | Oral | Lasix‑M | 50 | 0.78 | 1.90 |
|  | Tablet 40 mg | Oral | Lasix | 100 | 1.56 | 3.79 |
| Gliclazide | Tablet 60 mg (modified release) | Oral | Diamicron 60mg MR | 60 | 6.73 | 13.82 |
| Glimepiride | Tablet 1 mg | Oral | Amaryl | 30 | 0.90 | 2.98 |
|  | Tablet 2 mg | Oral | Amaryl | 30 | 1.72 | 3.75 |
|  | Tablet 3 mg | Oral | Amaryl | 30 | 2.19 | 4.22 |
|  | Tablet 4 mg | Oral | Amaryl | 30 | 2.70 | 4.73 |
| Hydrocortisone | Cream containing hydrocortisone acetate 10 mg per g, 50 g | Application | Sigmacort | 1 | 1.73 | 3.92 |
|  | Ointment containing hydrocortisone acetate 10 mg per g, 50 g | Application | Sigmacort | 1 | 1.73 | 3.92 |
|  | Tablet 4 mg | Oral | Hysone 4 | 50 | 13.45 | 16.24 |
|  | Tablet 20 mg | Oral | Hysone 20 | 60 | 19.20 | 21.99 |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the eye | Genteal | 1 | 2.08 | 6.12 |
| Hypromellose with Carbomer 980 | Ocular lubricating gel 3 mg‑2 mg per g, 10 g | Application to the eye | Genteal gel | 1 | 3.12 | 7.58 |
| Hypromellose with Dextran | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL | Application to the eye | Tears Naturale | 1 | 3.29 | 7.01 |
| Ibuprofen | Tablet 400 mg | Oral | Brufen | 30 | 1.79 | 4.58 |
| Imiquimod | Cream 50 mg per g, 2 g, 2 | Application | Aldara Pump | 1 | 70.25 | 74.48 |
|  | Cream 50 mg per g, 250 mg single use sachets, 12 | Application | Aldara | 1 | 70.25 | 72.37 |
| Indapamide | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | Oral | Natrilix SR | 90 | 7.17 | 13.82 |
|  | Tablet containing indapamide hemihydrate 2.5 mg | Oral | Natrilix | 90 | 4.91 | 11.96 |
| Indometacin | Capsule 25 mg | Oral | Indocid | 50 | 2.60 | 4.48 |
| Ipratropium | Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single units, 30 | Inhalation | Atrovent | 1 | 7.55 | 7.78 |
|  | Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single units, 30 | Inhalation | Atrovent Adult | 1 | 8.92 | 9.15 |
| Irbesartan | Tablet 75 mg | Oral | Avapro | 30 | 1.20 | 3.66 |
|  |  |  | Karvea | 30 | 1.20 | 3.66 |
|  | Tablet 150 mg | Oral | Avapro | 30 | 1.71 | 4.18 |
|  |  |  | Karvea | 30 | 1.71 | 4.18 |
|  | Tablet 300 mg | Oral | Avapro | 30 | 3.43 | 5.90 |
|  |  |  | Karvea | 30 | 3.43 | 5.90 |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg‑12.5 mg | Oral | Avapro HCT 150/12.5 | 30 | 1.96 | 4.43 |
|  |  |  | Karvezide 150/12.5 | 30 | 1.96 | 4.43 |
|  | Tablet 300 mg‑12.5 mg | Oral | Avapro HCT 300/12.5 | 30 | 3.60 | 6.06 |
|  |  |  | Karvezide 300/12.5 | 30 | 3.60 | 6.06 |
|  | Tablet 300 mg‑25 mg | Oral | Avapro HCT 300/25 | 30 | 3.92 | 6.38 |
|  |  |  | Karvezide 300/25 | 30 | 3.92 | 6.38 |
| Isosorbide Mononitrate | Tablet 60 mg (sustained release) | Oral | Imdur Durule | 30 | 3.42 | 6.56 |
|  |  |  | Monodur 60 mg | 30 | 3.42 | 5.73 |
|  | Tablet 120 mg (sustained release) | Oral | Imdur 120 mg | 30 | 6.81 | 9.94 |
| Ketoprofen | Capsule 200 mg (sustained release) | Oral | Orudis SR 200 | 28 | 10.26 | 12.04 |
| Labetalol | Tablet containing labetalol hydrochloride 100 mg | Oral | Trandate | 100 | 12.32 | 15.58 |
| Lamivudine | Tablet 100 mg | Oral | Zeffix | 28 | 34.70 | 35.30 |
| Lamotrigine | Tablet 25 mg | Oral | Lamictal | 56 | 5.18 | 6.68 |
|  | Tablet 50 mg | Oral | Lamictal | 56 | 8.63 | 9.97 |
|  | Tablet 100 mg | Oral | Lamictal | 56 | 14.37 | 15.77 |
|  | Tablet 200 mg | Oral | Lamictal | 56 | 24.15 | 25.54 |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | Zoton FasTabs | 28 | 2.92 | 7.39 |
|  | Tablet 30 mg (orally disintegrating) | Oral | Zoton FasTabs | 28 | 5.24 | 9.71 |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | Zanidip | 28 | 1.95 | 5.21 |
|  | Tablet containing lercanidipine hydrochloride 20 mg | Oral | Zanidip | 28 | 3.25 | 6.50 |
| Levonorgestrel with Ethinylestradiol | Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Oral | Levlen ED | 4 | 5.68 | 9.37 |
|  |  |  | Nordette 28 | 4 | 5.68 | 16.43 |
|  | Pack containing 6 tablets 50 micrograms‑30 micrograms, 5 tablets 75 micrograms‑40 micrograms, 10 tablets 125 micrograms‑30 micrograms and 7 inert tablets | Oral | Triphasil 28 | 4 | 7.18 | 19.27 |
|  |  |  | Triquilar ED | 4 | 7.18 | 19.79 |
| Levothyroxine | Tablet containing 50 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 13.71 | 15.49 |
|  | Tablet containing 75 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 14.23 | 16.07 |
|  | Tablet containing 100 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 14.20 | 15.99 |
|  | Tablet containing 200 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 16.65 | 18.44 |
| Lisinopril | Tablet 5 mg | Oral | Zestril | 30 | 2.01 | 6.51 |
|  | Tablet 10 mg | Oral | Zestril | 30 | 3.01 | 7.51 |
|  | Tablet 20 mg | Oral | Zestril | 30 | 3.79 | 8.29 |
| Medroxyprogesterone | Injection containing medroxyprogesterone acetate 150 mg in 1 mL | Injection | Depo‑Provera | 1 | 13.14 | 19.65 |
|  | Tablet containing medroxyprogesterone acetate 5 mg | Oral | Provera | 56 | 7.44 | 13.67 |
|  | Tablet containing medroxyprogesterone acetate 10 mg | Oral | Provera | 30 | 6.39 | 12.62 |
|  |  |  |  | 100 | ‑ | 27.53 |
| Meloxicam | Capsule 7.5 mg | Oral | Mobic | 30 | 2.60 | 5.39 |
|  | Capsule 15 mg | Oral | Mobic | 30 | 3.80 | 6.59 |
|  | Tablet 7.5 mg | Oral | Mobic | 30 | 2.60 | 5.39 |
|  | Tablet 15 mg | Oral | Mobic | 30 | 3.80 | 6.59 |
| Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Diabex | 100 | 2.50 | 7.11 |
|  | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Diabex XR 500 | 120 | 4.01 | 8.61 |
|  | Tablet containing metformin hydrochloride 850 mg | Oral | Diabex 850 | 60 | 2.50 | 7.11 |
|  | Tablet containing metformin hydrochloride 1 g | Oral | Diabex 1000 | 90 | 4.36 | 8.97 |
|  | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Diabex XR 1000 | 60 | 4.01 | 8.61 |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 10 mg | Oral | Ritalin 10 | 100 | 8.50 | 12.00 |
| Methylprednisolone | Injection containing methylprednisolone acetate 40 mg in 1 mL | Injection | Depo‑Medrol | 5 | 10.58 | 13.01 |
| Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | Maxolon | 25 | 1.05 | 2.83 |
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | Oral | Betaloc | 100 | 1.77 | 9.66 |
|  |  |  | Lopresor 50 | 100 | 1.77 | 3.44 |
|  | Tablet containing metoprolol tartrate 100 mg | Oral | Betaloc | 60 | 2.26 | 10.16 |
|  |  |  | Lopresor 100 | 60 | 2.26 | 3.93 |
| Metronidazole | Tablet 200 mg | Oral | Flagyl | 21 | 1.18 | 3.04 |
|  | Tablet 400 mg | Oral | Flagyl | 21 | 2.77 | 4.63 |
| Mirtazapine | Tablet 30 mg | Oral | Avanza | 30 | 3.35 | 8.00 |
| Moclobemide | Tablet 150 mg | Oral | Aurorix | 60 | 9.06 | 11.85 |
|  | Tablet 300 mg | Oral | Aurorix 300 mg | 60 | 15.13 | 17.92 |
| Mometasone | Cream containing mometasone furoate 1 mg per g, 15 g | Application | Elocon Alcohol Free | 1 | 3.08 | 6.36 |
|  | Lotion containing mometasone furoate 1 mg per g, 30 mL | Application | Elocon | 1 | 4.86 | 8.15 |
|  | Ointment containing mometasone furoate 1 mg per g, 15 g | Application | Elocon | 1 | 3.08 | 6.36 |
| Naproxen | Tablet 1 g (sustained release) | Oral | Naprosyn SR1000 | 28 | 6.10 | 7.14 |
|  | Tablet 750 mg (sustained release) | Oral | Naprosyn SR750 | 28 | 4.58 | 5.56 |
|  | Tablet containing naproxen sodium 550 mg | Oral | Anaprox 550 | 50 | 5.13 | 6.89 |
| Naratriptan | Tablet 2.5 mg (as hydrochloride) | Oral | Naramig | 2 | 6.40 | 7.31 |
| Nizatidine | Capsule 150 mg | Oral | Tazac | 60 | 9.71 | 15.86 |
|  | Capsule 300 mg | Oral | Tazac | 30 | 9.71 | 15.86 |
| Norethisterone with Ethinylestradiol | Pack containing 21 tablets 500 micrograms‑35 micrograms and 7 inert tablets | Oral | Brevinor | 4 | 8.12 | 17.22 |
|  | Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets | Oral | Brevinor‑1 | 4 | 8.12 | 17.22 |
| Olanzapine | Tablet 2.5 mg | Oral | Zyprexa | 28 | 2.58 | 5.37 |
|  | Tablet 5 mg | Oral | Zyprexa | 28 | 5.10 | 7.89 |
|  | Tablet 7.5 mg | Oral | Zyprexa | 28 | 7.73 | 10.52 |
|  | Tablet 10 mg | Oral | Zyprexa | 28 | 10.30 | 13.09 |
|  | Wafer 5 mg | Oral | Zyprexa Zydis | 28 | 5.10 | 7.89 |
|  | Wafer 10 mg | Oral | Zyprexa Zydis | 28 | 10.30 | 13.09 |
|  | Wafer 15 mg | Oral | Zyprexa Zydis | 28 | 15.45 | 18.24 |
|  | Wafer 20 mg | Oral | Zyprexa Zydis | 28 | 20.60 | 23.39 |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral | Olmetec | 30 | 3.83 | 7.09 |
|  | Tablet containing olmesartan medoxomil 40 mg | Oral | Olmetec | 30 | 8.13 | 11.39 |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | Sevikar 40/5 | 30 | 8.96 | 11.75 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | Sevikar 40/10 | 30 | 9.60 | 12.39 |
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 20/5/12.5 | 30 | 6.12 | 8.91 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/5/12.5 | 30 | 10.42 | 13.21 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/5/25 | 30 | 11.88 | 14.67 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/10/12.5 | 30 | 11.06 | 13.85 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/10/25 | 30 | 12.52 | 15.31 |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | Olmetec Plus | 30 | 4.57 | 6.04 |
|  | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | Olmetec Plus | 30 | 8.46 | 13.11 |
|  | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | Olmetec Plus | 30 | 9.57 | 11.05 |
| Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | 30 | 4.12 | 10.97 |
| Ondansetron | Wafer 4 mg | Oral | Zofran Zydis | 4 | 3.41 | 5.69 |
|  |  |  | Zofran Zydis | 10 | ‑ | 10.81 |
|  | Wafer 8 mg | Oral | Zofran Zydis | 4 | 5.35 | 7.63 |
|  |  |  | Zofran Zydis | 10 | ‑ | 15.66 |
| Oxazepam | Tablet 30 mg | Oral | Serepax | 25 | 1.00 | 3.17 |
| Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Endone | 20 | 1.81 | 3.67 |
| Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Refresh Night Time | 1 | 11.47 | 13.18 |
| Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Aropax | 30 | 3.18 | 5.58 |
| Perindopril | Tablet containing perindopril arginine 2.5 mg | Oral | Coversyl 2.5mg | 30 | 1.43 | 10.51 |
|  | Tablet containing perindopril arginine 5 mg | Oral | Coversyl 5mg | 30 | 2.66 | 11.45 |
|  | Tablet containing perindopril arginine 10 mg | Oral | Coversyl 10mg | 30 | 4.07 | 13.30 |
| Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) | Oral | Coveram 5/5 | 30 | 3.49 | 11.93 |
|  | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | Oral | Coveram 5/10 | 30 | 4.13 | 12.86 |
|  | Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) | Oral | Coveram 10/5 | 30 | 4.90 | 13.77 |
|  | Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) | Oral | Coveram 10/10 | 30 | 5.54 | 14.70 |
| Perindopril with indapamide | Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg | Oral | Coversyl Plus LD 2.5mg/0.625mg | 30 | 1.84 | 9.17 |
|  | Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg | Oral | Coversyl Plus 5mg/1.25mg | 30 | 3.48 | 10.12 |
|  | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Perindo Combi 4/1.25 | 30 | 3.48 | 6.21 |
| Piroxicam | Capsule 10 mg | Oral | Feldene | 50 | 4.68 | 12.12 |
|  | Capsule 20 mg | Oral | Feldene | 25 | 4.45 | 11.89 |
|  | Dispersible tablet 20 mg | Oral | Feldene‑D | 25 | 4.45 | 11.89 |
| Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | Cholstat 10 | 30 | 1.43 | 4.18 |
|  | Tablet containing pravastatin sodium 10 mg | Oral | Pravachol | 30 | 1.43 | 4.17 |
|  | Tablet containing pravastatin sodium 20 mg | Oral | Pravachol | 30 | 2.27 | 5.02 |
|  | Tablet containing pravastatin sodium 40 mg | Oral | Pravachol | 30 | 3.53 | 6.33 |
|  | Tablet containing pravastatin sodium 80 mg | Oral | Pravachol | 30 | 5.43 | 8.23 |
| Prednisolone | Oral solution 5 mg (as sodium phosphate) per mL, 30 mL | Oral | Redipred | 1 | 6.70 | 8.88 |
|  | Tablet 1 mg | Oral | Panafcortelone | 100 | 2.38 | 3.31 |
| Prednisone | Tablet 1 mg | Oral | Panafcort | 100 | 2.33 | 3.26 |
| Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg | Oral | Stemetil | 25 | 0.90 | 3.69 |
| Propranolol | Tablet containing propranolol hydrochloride 10 mg | Oral | Deralin 10 | 100 | 2.56 | 5.34 |
|  |  |  | Inderal | 100 | 2.56 | 10.45 |
|  | Tablet containing propranolol hydrochloride 40 mg | Oral | Deralin 40 | 100 | 2.81 | 5.59 |
|  |  |  | Inderal | 100 | 2.81 | 10.70 |
| Quetiapine | Tablet 25 mg (as fumarate) | Oral | Seroquel | 60 | 5.43 | 10.08 |
|  | Tablet (modified release) 50 mg (as fumarate) | Oral | Seroquel XR | 60 | 10.86 | 15.66 |
|  | Tablet 100 mg (as fumarate) | Oral | Seroquel | 90 | 15.36 | 20.01 |
|  | Tablet (modified release) 150 mg (as fumarate) | Oral | Seroquel XR | 60 | 15.36 | 25.36 |
|  | Tablet (modified release) 200 mg (as fumarate) | Oral | Seroquel XR | 60 | 31.60 | 33.60 |
|  | Tablet 200 mg (as fumarate) | Oral | Seroquel | 60 | 20.93 | 25.58 |
|  | Tablet (modified release) 300 mg (as fumarate) | Oral | Seroquel XR | 60 | 40.59 | 42.59 |
|  | Tablet 300 mg (as fumarate) | Oral | Seroquel | 60 | 30.72 | 35.37 |
|  | Tablet (modified release) 400 mg (as fumarate) | Oral | Seroquel XR | 60 | 55.33 | 57.33 |
| Quinapril | Tablet 5 mg (as hydrochloride) | Oral | Accupril | 30 | 2.91 | 6.82 |
|  | Tablet 10 mg (as hydrochloride) | Oral | Accupril | 30 | 3.71 | 7.62 |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Pariet | 28 | 2.83 | 7.49 |
|  | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Pariet | 30 | 2.83 | 7.49 |
| Ranitidine | Tablet 150 mg (as hydrochloride) | Oral | Zantac | 60 | 3.22 | 4.78 |
|  | Tablet 300 mg (as hydrochloride) | Oral | Zantac | 30 | 3.22 | 4.78 |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Crestor | 30 | 2.45 | 4.45 |
|  | Tablet 10 mg (as calcium) | Oral | Crestor | 30 | 3.16 | 5.16 |
|  | Tablet 20 mg (as calcium) | Oral | Crestor | 30 | 5.11 | 7.11 |
|  | Tablet 40 mg (as calcium) | Oral | Crestor | 30 | 7.30 | 10.20 |
| Roxithromycin | Tablet 150 mg | Oral | Rulide | 10 | 2.31 | 4.45 |
|  | Tablet 300 mg | Oral | Rulide | 5 | 2.31 | 4.45 |
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules | 20 | 2.48 | 4.04 |
|  | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation | Asmol 2.5 uni‑dose | 1 | 3.72 | 3.95 |
|  | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules | 1 | 2.61 | 4.16 |
|  | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation | Asmol 5 uni-dose | 1 | 3.92 | 4.15 |
|  | Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | Ventolin CFC-free | 1 | 3.90 | 5.60 |
|  | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by mouth | Ventolin CFC-Free with dose counter | 1 | 4.49 | 6.82 |
| Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Zoloft | 30 | 1.57 | 6.97 |
|  | Tablet 100 mg (as hydrochloride) | Oral | Zoloft | 30 | 1.57 | 6.97 |
| Simvastatin | Tablet 10 mg | Oral | Lipex 10 | 30 | 1.04 | 6.00 |
|  |  |  | Zocor | 30 | 1.04 | 6.00 |
|  | Tablet 20 mg | Oral | Lipex 20 | 30 | 1.51 | 8.48 |
|  |  |  | Zocor | 30 | 1.51 | 8.48 |
|  | Tablet 40 mg | Oral | Lipex 40 | 30 | 2.17 | 9.14 |
|  |  |  | Zocor | 30 | 2.17 | 9.14 |
| Sotalol | Tablet containing sotalol hydrochloride 80 mg | Oral | Sotacor | 60 | 2.99 | 7.01 |
|  | Tablet containing sotalol hydrochloride 160 mg | Oral | Sotacor | 60 | 6.43 | 10.45 |
| Spironolactone | Tablet 25 mg | Oral | Aldactone | 100 | 3.50 | 8.73 |
|  | Tablet 100 mg | Oral | Aldactone | 100 | 13.77 | 19.00 |
| Sulfasalazine | Tablet 500 mg (enteric coated) | Oral | Salazopyrin‑EN | 100 | 20.15 | 22.01 |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | Imigran | 2 | 2.40 | 4.35 |
|  |  |  |  | 4 |  | 8.70 |
|  | Tablet (fast disintegrating) 50 mg (as succinate) | Oral | Imigran FDT | 2 | 2.40 | 4.35 |
|  |  |  |  | 4 |  | 8.70 |
| Telmisartan | Tablet 40 mg | Oral | Micardis | 28 | 1.65 | 5.83 |
|  | Tablet 80 mg | Oral | Micardis | 28 | 4.78 | 8.97 |
| Telmisartan with amlodipine | Tablet 40 mg‑5 mg (as besilate) | Oral | Twynsta | 28 | 2.42 | 6.60 |
|  | Tablet 40 mg‑10 mg (as besilate) | Oral | Twynsta | 28 | 3.02 | 7.21 |
|  | Tablet 80 mg‑5 mg (as besilate) | Oral | Twynsta | 28 | 5.55 | 9.74 |
|  | Tablet 80 mg‑10 mg (as besilate) | Oral | Twynsta | 28 | 6.15 | 10.33 |
| Telmisartan with hydrochlorothiazide | Tablet 40 mg‑12.5 mg | Oral | Micardis Plus 40/12.5 mg | 28 | 2.12 | 6.31 |
|  | Tablet 80 mg‑12.5 mg | Oral | Micardis Plus 80/12.5 mg | 28 | 5.29 | 9.48 |
|  | Tablet 80 mg‑25 mg | Oral | Micardis Plus 80/25 mg | 28 | 5.76 | 9.94 |
| Temazepam | Tablet 10 mg | Oral | Normison | 25 | 1.00 | 4.24 |
| Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramal | 20 | 1.86 | 4.11 |
|  | Tablet (sustained release) containing tramadol hydrochloride 100 mg | Oral | Tramal SR 100 | 20 | 2.24 | 6.42 |
|  | Tablet (sustained release) containing tramadol hydrochloride 150 mg | Oral | Tramal SR 150 | 20 | 3.00 | 8.00 |
|  | Tablet (sustained release) containing tramadol hydrochloride 200 mg | Oral | Tramal SR 200 | 20 | 3.66 | 9.32 |
| Trandolapril | Capsule 500 micrograms | Oral | Gopten | 28 | 1.96 | 5.22 |
|  | Capsule 1 mg | Oral | Gopten | 28 | 3.69 | 6.95 |
|  | Capsule 2 mg | Oral | Gopten | 28 | 4.45 | 7.70 |
|  | Capsule 4 mg | Oral | Gopten | 28 | 8.36 | 11.61 |
| Triamcinolone | Cream containing triamcinolone acetonide 200 micrograms per g, 100 g | Application | Aristocort 0.02% | 1 | 3.23 | 4.75 |
|  | Ointment containing triamcinolone acetonide 200 micrograms per g, 100 g | Application | Aristocort 0.02% | 1 | 3.23 | 4.75 |
| Triamcinolone with Neomycin, Gramicidin and Nystatin | Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per g, 7.5 mL | Application to the ear | Kenacomb Otic | 1 | 3.78 | 5.36 |
|  | Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g | Application to the ear | Kenacomb Otic | 1 | 1.42 | 3.00 |
| Trimethoprim | Tablet 300 mg | Oral | Triprim | 7 | 1.58 | 5.00 |
| Trimethoprim with Sulfamethoxazole | Tablet 160 mg‑800 mg | Oral | Septrin Forte | 10 | 1.76 | 5.64 |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valtrex | 10 | 4.42 | 5.47 |
|  |  |  | Valtrex | 30 |  | 15.36 |
|  |  |  | Valtrex | 42 |  | 20.67 |
|  |  |  | Valtrex | 100 |  | 44.64 |
| Valproic Acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Epilim EC | 100 | 5.46 | 6.39 |
|  | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Epilim EC | 100 | 10.81 | 11.74 |
| Verapamil | Tablet containing verapamil hydrochloride 80 mg | Oral | Isoptin | 100 | 6.95 | 10.20 |
|  | Tablet containing verapamil hydrochloride 180 mg (sustained release) | Oral | Isoptin 180 SR | 30 | 5.61 | 8.86 |
|  | Tablet containing verapamil hydrochloride 240 mg (sustained release) | Oral | Isoptin SR | 30 | 7.48 | 10.73 |
| Zolmitriptan | Tablet 2.5 mg | Oral | Zomig | 2 | 5.52 | 6.81 |

Schedule 2—Pharmaceutical benefits for which the Commonwealth will pay the special patient contribution

(section 7)

| **Listed Drug** | **Form** | **Manner of Administration** | **Brand** | **Circumstances** |
| --- | --- | --- | --- | --- |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | Infection suspected or proven to be due to a susceptible organism  The treatment must be for patients who require a liquid formulation and in whom the syrup formulations are unsuitable |
| Eprosartan | Tablet 400 mg (as mesilate) | Oral | Teveten | Adverse effects occurring with all of the base‑priced drugs.  Drug interactions occurring with all of the base‑priced drugs.  Drug interactions expected to occur with all of the base‑priced drugs.  Transfer to a base‑priced drug would cause patient confusion resulting in problems with compliance. |
|  | Tablet 600 mg (as mesilate) | Oral | Teveten | Adverse effects occurring with all of the base‑priced drugs.  Drug interactions occurring with all of the base‑priced drugs.  Drug interactions expected to occur with all of the base‑priced drugs.  Transfer to a base‑priced drug would cause patient confusion resulting in problems with compliance. |
| Naratriptan | Tablet 2.5 mg (as hydrochloride) | Oral | Naramig | Migraine attack  The condition must have usually failed to respond to analgesics in the past; AND  Patient must be one in whom transfer to another suitable PBS‑listed drug would cause patient confusion resulting in problems with compliance. |
|  |  |  |  | Migraine attack  The condition must have usually failed to respond to analgesics in the past; AND  Patient must be one in whom transfer to another suitable PBS‑listed drug is likely to result in adverse clinical consequences. |
|  |  |  |  | Migraine attack  The condition must have usually failed to respond to analgesics in the past; AND  Patient must be one in whom adverse events have occurred with other suitable PBS‑listed drugs. |
|  |  |  |  | Migraine attack  The condition must have usually failed to respond to analgesics in the past; AND  Patient must be one in whom drug interactions are expected to occur with other suitable PBS‑listed drugs. |
|  |  |  |  | Migraine attack  The condition must have usually failed to respond to analgesics in the past; AND  Patient must be one in whom drug interactions have occurred with other suitable PBS‑listed drugs. |

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Editorial changes**

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = *Legislation Act 2003* | Sch = Schedule(s) |
| LIA = *Legislative Instruments Act 2003* | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |

Endnote 3—Legislation history

| Name | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| PB 109 of 2010 | 30 Nov 2010 (F2010L03136) | 1 Dec 2010 (s 2) |  |
| PB 6 of 2011 | 28 Jan 2011 (F2011L00165) | 1 Feb 2011 (s 2) | — |
| PB 15 of 2011 | 23 Feb 2011 (F2011L00298) | 1 Mar 2011 (s 2) | — |
| PB 25 of 2011 | 25 Mar 2011 (F2011L00490) | s 1–3: 26 Mar 2011 Sch 1: 1 Apr 2011 (s 2(1)) Sch 2: 2 Apr 2011 (s 2(2)) | — |
| PB 43 of 2011 | 15 June 2011 (F2011L01051) | 1 July 2011 (s 2) | — |
| PB 50 of 2011 | 27 July 2011 (F2011L01546) | 1 Aug 2011 (s 2) | — |
| PB 58 of 2011 | 29 Aug 2011 (F2011L01763) | 1 Sept 2011 (s 2) | — |
| PB 75 of 2011 | 26 Oct 2011 (F2011L02131) | 1 Nov 2011 (s 2) | — |
| PB 84 of 2011 | 28 Nov 2011 (F2011L02476) | 1 Dec 2011 (s 2) | — |
| PB 2 of 2012 | 13 Feb 2012 (F2012L00272) | 1 Mar 2012 (s 2) | — |
| PB 14 of 2012 | 30 Mar 2012 (F2012L00723) | s 1–3 and Sch 1: 1 Apr 2011 (s 2(1)) Sch 2: 1 Apr 2012 (s 2(2)) | — |
| PB 28 of 2012 | 26 Apr 2012 (F2012L00936) | 1 May 2012 (s 2) | — |
| PB 45 of 2012 | 25 July 2012 (F2012L01599) | 1 Aug 2012 (s 2) | — |
| PB 61 of 2012 | 15 Aug 2012 (F2012L01682) | 1 Sept 2012 (s 2) | — |
| PB 72 of 2012 | 27 Sept 2012 (F2012L01952) | 1 Oct 2012 (s 2) | — |
| PB 94 of 2012 | 29 Nov 2012 (F2012L02284) | 1 Dec 2012 (s 2) | — |
| PB 109 of 2012 | 18 Dec 2012 (F2012L02511) | 1 Jan 2013 (s 2) | — |
| PB 2 of 2013 | 10 Jan 2013 (F2013L00040) | 1 Feb 2013 (s 2) | — |
| PB 15 of 2013 | 26 Mar 2013 (F2013L00559) | 1 Apr 2013 (s 2) | — |
| PB 22 of 2013 | 23 Apr 2013 (F2013L00678) | 1 May 2013 (s 2) | — |
| PB 41 of 2013 | 29 July 2013 (F2013L01457 | 1 Aug 2013 (s 2) | — |
| PB 54 of 2013 | 15 Aug 2013 (F2013L01579) | 1 Sept 2013 (s 2) | — |
| PB 62 of 2013 | 10 Sept 2013 (F2013L01681) | 1 Oct 2013 (s 2) | — |
| PB 75 of 2013 | 28 Nov 2013 (F2013L02007) | 1 Dec 2013 (s 2) | — |
| PB 89 of 2013 | 20 Dec 2013 (F2013L02169) | 1 Jan 2014 (s 2) | — |
| PB 2 of 2014 | 10 Jan 2014 (F2014L00052) | 1 Feb 2014 (s 2) | — |
| PB 18 of 2014 | 26 Mar 2014 (F2014L00356) | 1 Apr 2014 (s 2) | — |
| PB 28 of 2014 | 11 Apr 2014 (F2014L00400) | 1 May 2014 (s 2) | — |
| PB 37 of 2014 | 21 May 2014 (F2014L00589) | 1 June 2014 (s 2) | — |
| PB 53 of 2014 | 31 July 2014 (F2014L01063) | 1 Aug 2014 (s 2) | — |
| PB 73 of 2014 | 26 Sept 2014 (F2014L01289) | 1 Oct 2014 (s 2) | — |
| PB 89 of 2014 | 27 Nov 2014 (F2014L01597) | 1 Dec 2014 (s 2) | — |
| PB 11 of 2015 | 25 Feb 2015 (F2015L00208) | 1 Mar 2015 (s 2) | — |
| PB 27 of 2015 | 25 Mar 2015 (F2015L00333) | 1 Apr 2015 (s 2) | — |
| PB 40 of 2015 | 24 Apr 2015 (F2015L00590) | 1 May 2015 (s 2) | — |
| PB 48 of 2015 | 29 May 2015 (F2015L00763) | 1 June 2015 (s 2) | — |
| PB 69 of 2015 | 31 July 2015 (F2015L01204) | 1 Aug 2015 (s 2) | — |
| PB 79 of 2015 | 28 Aug 2015 (F2015L01352) | 1 Sept 2015 (s 2) | — |
| PB 91 of 2015 | 30 Sept 2015 (F2015L01537) | 1 Oct 2015 (s 2) | — |
| PB 102 of 2015 | 28 Oct 2015 (F2015L01703) | 1 Nov 2015 (s 2) | — |
| PB 108 of 2015 | 30 Nov 2015 (F2015L01874) | 1 Dec 2015 (s 2) | — |
| PB 118 of 2015 | 24 Dec 2015 (F2015L02131) | 1 Jan 2016 (s 2) | — |
| PB 2 of 2016 | 1 Feb 2016 (F2016L00073) | 1 Feb 2016 (s 2) | — |
| PB 19 of 2016 | 1 Apr 2016 (F2016L00478) | 1 Apr 2016 (s 2) | — |
| PB 30 of 2016 | 29 Apr 2016 (F2016L00600) | 1 May 2016 (s 2) | — |
| PB 42 of 2016 | 30 May 2016 (F2016L00861) | 1 June 2016 (s 2) | — |
| PB 63 of 2016 | 19 July 2016 (F2016L01189) | 1 Aug 2016 (s 2) | — |
| PB 73 of 2016 | 18 Aug 2016 (F2016L01305) | 1 Sept 2016 (s 2) | — |
| PB 82 of 2016 | 30 Sept 2016 (F2016L01563) | 1 Oct 2016 (s 2) | — |
| PB 91 of 2016 | 31 Oct 2016 (F2016L01688) | 1 Nov 2016 (s 2) | — |
| PB 98 of 2016 | 30 Nov 2016 (F2016L01839) | 1 Dec 2016 (s 2) | — |
| PB 2 of 2017 | 25 Jan 2017 (F2017L00072) | 1 Feb 2017 (s 2) | — |
| PB 16 of 2017 | 30 Mar 2017 (F2017L00357) | 1 Apr 2017 (s 2) | — |
| PB 27 of 2017 | 28 Apr 2017 (F2017L00482) | 1 May 2017 (s 2) | — |
| PB 35 of 2017 | 31 May 2017 (F2017L00618) | 1 June 2017 (s 2) | — |
| PB 56 of 2017 | 25 July 2017 (F2017L00950) | 1 Aug 2017 (s 2) | — |
| PB 63 of 2017 | 30 Aug 2017 (F2017L01111) | 1 Sept 2017 (s 2) | — |
| PB 72 of 2017 | 26 Sept 2017 (F2017L01251) | 1 Oct 2017 (s 2) | — |
| PB 85 of 2017 | 24 Oct 2017 (F2017L01384) | 1 Nov 2017 (s 2) | — |
| PB 93 of 2017 | 29 Nov 2017 (F2017L01546) | 1 Dec 2017 (s 2) | — |
| PB 102 of 2017 | 18 Dec 2017 (F2017L01642) | 1 Jan 2018 (s 2) | — |
| PB 2 of 2018 | 24 Jan 2018 (F2018L00058) | 1 Feb 2018 (s 2) | — |
| PB 20 of 2018 | 28 Mar 2018 (F2018L00432) | 1 Apr 2018 (s 2) | — |
| PB 30 of 2018 | 30 Apr 2018 (F2018L00533) | 1 May 2018 (s 2) | — |
| PB 37 of 2018 | 31 May 2018 (F2018L00698) | 1 June 2018 (s 2) | — |
| PB 51 of 2018 | 29 June 2018 (F2018L00974) | 1 July 2018 (s 2) | — |
| PB 73 of 2018 | 31 July 2018 (F2018L01070) | 1 Aug 2018 (s 2) | — |
| PB 89 of 2018 | 27 Sept 2018 (F2018L01353) | 1 Oct 2018 (s 2) | — |
| PB 98 of 2018 | 29 Oct 2018 (F2018L01495) | 1 Nov 2018 (s 2) | — |
| PB 106 of 2018 | 29 Nov 2018 (F2018L01637) | 1 Dec 2018 (s 2) | — |
| PB 115 of 2018 | 20 Dec 2018 (F2018L01811) | 1 Jan 2019 (s 2) | — |
| PB 7 of 2019 | 31 Jan 2019 (F2019L00080) | 1 Feb 2019 (s 2) | — |
| PB 16 of 2019 | 27 Feb 2019 (F2019L00207) | 1 Mar 2019 (s 2) | — |
| PB 26 of 2019 | 29 Mar 2019 (F2019L00466) | 1 Apr 2019 (s 2) | — |
| PB 35 of 2019 | 30 Apr 2019 (F2019L00658) | 1 May 2019 (s 2) | — |
| PB 43 of 2019 | 30 May 2019 (F2019L00700) | 1 June 2019 (s 2) | — |
| PB 54 of 2019 | 28 June 2019 (F2019L00910) | 1 July 2019 (s 2) | — |
| PB 65 of 2019 | 30 July 2019 (F2019L01018) | 1 Aug 2019 (s 2) | — |
| PB 74 of 2019 | 30 Aug 2019 (F2019L01126) | 1 Sept 2019 (s 2) | — |
| PB 83 of 2019 | 30 Sept 2019 (F2019L01293) | 1 Oct 2019 (s 2) | — |
| PB 91 of 2019 | 31 Oct 2019 (F2019L01398) | 1 Nov 2019 (s 2) | — |
| PB 100 of 2019 | 27 Nov 2019 (F2019L01511) | 1 Dec 2019 (s 2) | — |
| PB 10 of 2020 | 30 Jan 2020 (F2020L00067) | 1 Feb 2020 (s 2) | — |
| PB 30 of 2020 | 31 Mar 2020 (F2020L00360) | 1 Apr 2020 (s 2) | — |
| PB 40 of 2020 | 30 Apr 2020 (F2020L00534) | 1 May 2020 (s 2) | — |
| PB 50 of 2020 | 29 May 2020 (F2020L00648) | 1 June 2020 (s 2) | — |
| PB 62 of 2020 | 30 June 2020 (F2020L00849) | 1 July 2020 (s 2) | — |
| PB 75 of 2020 | 31 July 2020 (F2020L00972) | 1 Aug 2020 (s 2) | — |
| PB 86 of 2020 | 28 Aug 2020 (F2020L01092) | 1 Sept 2020 (s 2(1) item 1) | — |
| PB 97 of 2020 | 30 Sept 2020 (F2020L01258) | 1 Oct 2020 (s 2(1) item 1) | — |
| PB 110 of 2020 | 30 Oct 2020 (F2020L01364) | 1 Nov 2020 (s 2(1) item 1) | — |
| PB 119 of 2020 | 27 Nov 2020 (F2020L01489) | 1 Dec 2020 (s 2(1) item 1) | — |
| PB 8 of 2021 | 28 Jan 2021 (F2021L00083) | 1 Feb 2021 (s 2(1) item 1) | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| s 2 | rep LA s 48D |
| s 3 | rep LA s 48C |
| s 4 | am PB 72 of 2012 |
| s 5 | rs PB 72 of 2012 |
| s 6 | rs PB 72 of 2012 |
| s 7 | am PB 58 of 2011; PB 72 of 2012 |
| **Schedule 1** |  |
| Schedule 1 | rs PB 6 of 2011 |
|  | am PB 15, 25, 43, 50, 58, 75 and 84 of 2011; PB 2, 14, 28, 45 and 61 of 2012 |
|  | rs PB 72 of 2012 |
|  | am PB 94 and 109 of 2012; PB 2, 15, 22, 41, 54, 62, 75 and 89 of 2013; PB 2, 18, 28, 37, 53, 73 and 89 of 2014; PB 11, 27, 40, 48, 69, 79, 91, 102, 108 and 118 of 2015; PB 2, 19, 30 and 42 of 2016; PB 63 of 2016; PB 73 of 2016; PB 82 of 2016; PB 91 of 2016; PB 98 of 2016; PB 2 of 2017; PB 16 of 2017; PB 27 of 2017; PB 35 of 2017; PB 56 of 2017; PB 63 of 2017; PB 72 of 2017; PB 85 of 2017; PB 93 of 2017; PB 102 of 2017; PB 2 of 2018; PB 20 of 2018; PB 30 of 2018; PB 37 of 2018; PB 51 of 2018 |
|  | ed C66 |
|  | am PB 73 of 2018; PB 89 of 2018 |
|  | ed C68 |
|  | am PB 98 of 2018; PB 106 of 2018 |
|  | ed C70 |
|  | am PB 115 of 2018; PB 7 of 2019; PB 16 of 2019; PB 26 of 2019; PB 35 of 2019; PB 43 of 2019; PB 54 of 2019; PB 65 of 2019 |
|  | ed C78 |
|  | am PB 74 of 2019 |
|  | ed C79 |
|  | am PB 83 of 2019; PB 91 of 2019; PB 100 of 2019; PB 10 of 2020 |
|  | ed C83 |
|  | am PB 30 of 2020; PB 40 of 2020; PB 50 of 2020; PB 62 of 2020; PB 75 of 2020 |
|  | ed C88 |
|  | am PB 86 of 2020; PB 97 of 2020 |
|  | ed C90 |
|  | am PB 110 of 2020 |
|  | ed C91 |
|  | am PB 119 of 2020 |
|  | ed C92 |
|  | am PB 8 of 2021 |
| **Schedule 2** |  |
| Schedule 2 | am PB 15 and 25 of 2011; PB 14 of 2012; PB 22, 41 and 62 of 2013; PB 53 of 2014; PB 98 of 2016; PB 51 of 2018; PB 83 of 2019 |